XPENG-MOTORS
9.6.2020 19:04:05 CEST | Business Wire | Press release
Xpeng Motors, a leading electric vehicle and technology company, today reveals an exclusive inside view into its self-built wholly-owned factory in Zhaoqing, Guangdong Province.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005686/en/
The Zhaoqing Xpeng Motors Intelligent Industrial Park, birthplace of the super-long range sports sedan Xpeng P7, was built over a period of 15 months. On May 19, 2020 the factory received the official production license from China’s Ministry of Industry and Information Technology.
Find the pictures and videos revealing the interior of the factory here: https://drive.google.com/drive/folders/1RzxP_eVWDWwVdnfaYTt01G7hn3F-ZZeS?usp=sharing
“We are deeply proud of our achievement as a young company, in building our own wholly-owned smart manufacture base at Zhaoqing,” said He Xiaopeng, Chairman and CEO of Xpeng Motors.
“Xpeng is now the only new smart EV maker in China that has both self-owned and contracted plants. We are a firm believer that manufacturing is the foundation of smart cars. Only when you build solid powertrain and vehicle hardware, can you differentiate with data operation, autonomous driving and connectivity software,” He added.
“This not only gives us optimal insight into and control over our production process, it also demonstrates our capabilities in successfully managing our supply chain and executing major projects. This is a great base for future development in intelligent vehicle design and manufacture,” He concluded.
Spanning a planned area of 3,000 acres (2 million square metres), it has five cutting-edge workshops including stamping, welding, painting, final assembly, and battery pack production.
The factory is run by a 600-member professional team. 74% of the engineers are with 5+ year working experience with 78% joined from leading OEMs.
Stamping Workshop
The stamping workshop is 100% automated. Steel plates are stamped and formed on the 6,600-ton large CNC (computer numerical control) automatic stamping production line, delivering as many as 12 pieces per minute, higher than the 10% industry average, with a precision range as narrow as 0.1 millimeter.
Equipped with an industry-leading information system, the production process is highly open and transparent, with real-time monitoring of processing parameters to ensure high quality consistency.
Welding Workshop
The Zhaoqing welding workshop is equipped with 210 ABB industrial robots, meticulously performing multiple processes including gluing, welding and aluminum plate riveting. Tier-1 and Tier-2 final assemblies reach a 100% automation rate, with the capability to manufacture steel-aluminum hybrid vehicle bodies.
The factory’s self-adaptive medium frequency welding machine achieves 30% energy saving, while the advanced visual gluing system yields gluing accuracy as fine as 0.5 millimeter.
Painting Workshop
Sophisticated styling requires exceptional painting techniques. The Zhaoqing factory’s thin film pretreatment and cathode electrophoretic technology effectively reduces wastewater discharge, while slag yield is also cut down by 94%, reducing energy consumption by approximately 25%, and achieving zero emission of heavy metal pollutants.
The painting workshop adopts world-class BASF high-throwing-power coating material, with B1B2+2K water-based varnish double-layer painting technology, significantly improving paint quality while protecting the environment too.
Assembly Workshop
Thanks to an automatic material supply and distribution system, AGV technology, automatic gluing robots and assembly technology, all components are efficiently and meticulously assembled in the Zhaoqing factory.
All the key torque joints of CBUs (Complete Built Up) are tested online through a powerful digital production system, ensuring 100% quality control of all key torque joints of the build-up.
Battery Pack Workshop
The pack workshop utilizes an AGV flexible production line, combining high-precision visual systems and robots to execute intelligent operations. The intelligent end-of-line testing system conducts comprehensive testing – including 198 offline tests and 89 battery performance tests - for every battery pack, including insulation, SOC performance and BMS function to ensure that every battery pack meets the industry-leading IP68 sealing protection requirements.
The Xpeng P7 will go through 18 vigorous quality control procedures. Each vehicle will also go through over 1,700 dynamic and static tests, and 18 simulated road condition tests for control, braking, comfort, sealing, and abnormal sound to guarantee its quality.
Zhaoqing Xpeng Motors Intelligent Industrial Park – At a Glance
- Total planned area: 3,000 acres (2 million square metres)
- Vehicle production facilities area: 1,500 acres (1 million square metres).
- Phase 1 construction: 900 acres (600,000 square metres)
- Foundation-laying: December 2017
- Construction completion: September 2019
- MIIT production license: received on 19 May 2020
- Industry 4.0 standards
- Five workshops
- 264 intelligent industrial robots
For more P7 videos and images please visit: https://drive.google.com/open?id=1mjds6n51HszTF5YhDcbaViucSwLjeiio
About XPENG Motors
Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/
Follow us on social media for latest Xpeng news:
Facebook Twitter LinkedIn YouTube Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005686/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
